Taurine supplementation in high-fat diet fed male mice attenuates endocrine pancreatic dysfunction in their male offspring

Amino Acids. 2019 Apr;51(4):727-738. doi: 10.1007/s00726-019-02712-7. Epub 2019 Mar 4.

Abstract

Obesity in fathers leads to DNA damage and epigenetic changes in sperm that may carry potential risk factors for metabolic diseases to the next generation. Taurine (TAU) supplementation has demonstrated benefits against testicular dysfunction and pancreatic islet impairments induced by obesity, but it is not known if these protective actions prevent the propagation of metabolic disruptions to the next generation; as such, we hypothesized that paternal obesity may increase the probability of endocrine pancreatic dysfunction in offspring, and that this could be prevented by TAU supplementation in male progenitors. To test this, male C57Bl/6 mice were fed on a control diet (CTL) or a high-fat diet (HFD) without or with 5% TAU in their drinking water (CTAU and HTAU) for 4 months. Subsequently, all groups of mice were mated with CTL females, and the F1 offspring were identified as: CTL-F1, CTAU-F1, HFD-F1, and HTAU-F1. HFD-fed mice were normoglycemic, but glucose intolerant and their islets hypersecreted insulin. However, at 90 days of age, HFD-F1 offspring displayed normal glucose homeostasis and adiposity, but reduced glucose-induced insulin release. HFD-F1 islets also exhibited β- and α-cell hypotrophy, and lower δ-cell number per islet. Paternal TAU supplementation prevented the decrease in glucose-induced insulin secretion and normalized β-cell size and δ-cell number, and increased α-cell size/islet in HTAU-F1 mice. In conclusion, HFD consumption by male founders decreases β-cell secretion and islet-cell distribution in their offspring. TAU attenuates the deleterious effects of paternal obesity on insulin secretion and islet-cell morphology in F1 offspring.

Keywords: Insulin secretion; Islet morphology; Metabolic programming; Paternal obesity; Taurine.

MeSH terms

  • Animals
  • Diet, High-Fat / adverse effects*
  • Dietary Supplements*
  • Endocrine System / drug effects*
  • Endocrine System / physiopathology
  • Glucose Intolerance / drug therapy*
  • Glucose Intolerance / etiology
  • Glucose Intolerance / pathology
  • Homeostasis
  • Insulin Secretion
  • Islets of Langerhans / drug effects*
  • Islets of Langerhans / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Obesity / physiopathology
  • Pancreatic Diseases / drug therapy*
  • Pancreatic Diseases / etiology
  • Pancreatic Diseases / pathology
  • Taurine / administration & dosage*

Substances

  • Taurine